Time

Event

8:00 am – Lobby

Registration

8:55 am – 2nd Floor

Welcome Back
* Sara Jane Demy, Founder & CEO, Demy-Colton

9:00 am – 2nd Floor

Fireside Chat
The Convergence of AI and Biomanufacturing: Pioneering the Future of Regenerative Medicine
In this fireside chat, experts will discuss how AI-driven breakthroughs in biomanufacturing are transforming the field of regenerative medicine. The conversation will explore how cutting-edge technologies are enabling the creation of living medicines that can regenerate tissues and organs, offering hope for curative solutions to diseases like Parkinson’s, macular degeneration, and other age-related conditions linked to cellular degeneration.
This fireside chat will discuss:
• The transition from traditional therapeutics to personalized cellular therapy.
• How living medicines derived from a patient’s own cells can potentially cure chronic diseases.
• The challenges and opportunities in scaling regenerative medicines for widespread use.
• Current advancements in biomanufacturing for cell therapies.

* Susan Hockfield, Professor, Neuroscience & President Emerita, MIT
* Nabiha Saklayen, CEO & Co-Founder, Cellino
Interviewed by : Kimberly Ha, Founder & CEO, KKH Advisors

10:00 am – 12th Floor

One-to-One Meetings

10:00 am – 12th Floor

Presenting Companies

11:00 am – 12th Floor

Dialogue 6A
Real Use of AI in Pharma: Today and in the Near Future
This panel will explore the continuously evolving uses of AI in the pharmaceutical and biotech industries, and the impact it can have thanks to its multiple cutting-edge applications. The conversation, powered by this group of life science leaders’ unique insights on the topic, will cover the groundbreaking effects of AI on the landscape, from powering new drug discovery platforms to accelerating clinical trials and increasing efficiency across the whole drug development process, ultimately improving patient outcomes.

Moderator: David Schull, President, Russo Partners

Panel:
* Xiaorong He, Senior Vice President, Head, Global Development Sciences & US Site Head of Non-Clinical Development, Boehringer Ingelheim Pharmaceuticals, Inc.
* Nathan McBride, Senior Vice President, IT, Xilio Therapeutics
* Friso Postma, VP, Artificial Intelligence Drug Discovery, BioXcel Therapeutics
* Kfir Schreiber, Co-Founder & CEO, DeepCure

11:00 am – Rooftop

Dialogue 6B
Emerging Technologies and Approaches in Cell & Gene Therapy
As the field of cell and gene therapy rapidly evolves, novel technologies and innovative approaches like AI/ML are pushing the boundaries of what’s possible. Experts will discuss how emerging technologies are overcoming current limitations, improving precision, and accelerating the path from research to clinical application to pave the way for more effective and accessible cell and gene therapies.

Moderator: Lei Lei Wu, News Reporter, Endpoints News

Panel:
* Paul Bresge, CEO, Ray Therapeutics
* Parastoo Khoshakhlagh, CEO & Co-Founder, GC Therapeutics 
* Kate Rochlin, COO, IN8bio
* Lexi Rovner, CEO, 64x Bio

12:00 pm – 2nd Floor

BioGENEius Award

12:10 pm – 2nd Floor

“Big Think” Plenary Session
Alternative Financing: Seeds of Creativity
A candid and critical discussion on how to obtain alternative funding in a challenging life sciences capital markets.

Moderator: Steve Brozak, Managing Partner & President, WBB Securities

Panel:
* Ross Barrett, Managing Director, Cancer Focus Fund
* George Santo, Managing Director, Head of Northeast Life Sciences Commercial Banking, J.P. Morgan
* Joseph Shonkwiler, COO, Advanced Research Projects Agency for Health (ARPA-H)
* Tingting Zhang-Kharas, Head, JLABS US Northeast, Johnson & Johnson Innovation

1:10 pm – 12th Floor

Luncheon

2:00 pm – 12th Floor

One-to-One Meetings

2:00 pm – 12th Floor

Dialogue 7A
Cardiovascular Disease in the Surging Age of Obesity Drugs
GLP-1 drugs are projected to become the biggest drug class in history, with estimated annual US sales of $100B to $130B by the end of the decade.  Yet, cardiovascular disease (CVD) has for the past century been, and for the foreseeable future will continue to be, the leading cause of death.  GLP-1 drugs may slow chronic disease epidemics such as obesity and diabetes, but CVD will continue to be the leading co-morbidity of those chronic diseases, and CVD needs to continue to be a top priority for drug discovery and development, for the obese and non-obese alike.  What are coming innovations and continued unmet needs in CVD, as we peer into the BioFuture?

Moderator: Thomas Seoh, President & CEO, Kinexum Services

Panel:
* Dawn Bell, CEO, Antlia Bioscience, Inc.
* Sophie Jones, Managing Director, JPMorgan Healthcare Investment Bank
* Minji Kim, Chief Business Officer, Mineralys Therapeutics, Inc.
* Alison Schecter, CEO, Molecules to Medicine Advisory Group

2:00 pm – Rooftop

Dialogue 7B

3:00 pm – 12th Floor

Dialogue 8A
Women’s Health: It’s About Time! It’s About the Healthcare for Women

Moderator: Matthew Arnold, Principal Analyst & Content Strategist, Clarivate

Panel:
* Jessica Federer, Investor & Board Member, Angelini Ventures
* Seema Kumar, CEO, Cure
* Stacey Seltzer, Managing Partner & Founder, Pontiva Healthcare Partners
* Stella Vnook, Co-Founder & Board Member, Kaida BioPharma

3:00 pm – Rooftop

Dialogue 8B

The Future of Radiopharmaceuticals: Emerging Isotopes will Drive Breakthroughs in Oncology
In recent years, significant advancements have been made in the development of Pb-based alpha particle therapies, presenting promising new avenues for cancer treatment and enhanced diagnostic accuracy. Numerous studies have demonstrated the superior efficacy of these therapies against various cancer indications. However, questions remain regarding the long-term integration of lead in precision medicine. The panel will identify key isotopes, their potential applications, and the required quantities to meet anticipated healthcare needs.

Moderator: Jeff Bockman, Expert Advisor, Executive Vice President, Oncology, Lumanity

Panel:
* Ashley Mishoe, VP, Regulatory Affairs & Quality Assurance, PharmaLogic Holdings
* Bill Riddoch, VP, Product Development & Engineering, BWXT
* Thijs Spoor, CEO, Perspective Therapeutics
* Thom Tulip, CBO, Radiopharm Theranostics

4:00 pm – 2nd Floor

Closing “Big Think” Plenary Session
Heard Around the Street: What’s Buzzing in Biotech

Moderator: Kimberly Ha, Founder & CEO, KKH Advisors

Panel:
* Max Bayer, Pharma Reporter, Endpoints News
* Hilary Brueck, Health Correspondent, Business Insider
* Sony Salzman, Coordinating Producer, Medical Unit, ABC News
* Uduak Thomas, Senior Editor, Genetic Engineering & Biotechnology News